Ontology highlight
ABSTRACT:
SUBMITTER: Liakos A
PROVIDER: S-EPMC4406879 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
Liakos Aris A Karagiannis Thomas T Bekiari Eleni E Boura Panagiota P Tsapas Apostolos A
Therapeutic advances in endocrinology and metabolism 20150401 2
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and the US for use in patients with type 2 diabetes. This review summarizes current evidence from clinical trials assessing the clinical efficacy and safety of dapagliflozin, and presents data regarding its cost-effectiveness. Treatment with dapaglifl ...[more]